Leverkusen, Germany, March 13, 2020 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement.
Leverkusen, Germany, April 16, 2020 -- The Annual General Meeting of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) shall be held on May 28, 2020. Today, the.
NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Biofrontera AG (NASDAQ:BFRA) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 20, 2020 at 2:00 PM Eastern ...
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that it has adopted comprehensive measures to reduce costs during the global COVID-19 pandemic. Biofrontera management anticipates declining demand for its product Ameluz® due to current measures and regulations implemented by governments worldwide in an attempt to control the COVID-19 pandemic. As such, the company must be prepared for a transiently declining global demand for Biofrontera’s products due to the Coronavirus pandemic.
BFRA earnings call for the period ending March 31, 2020.
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, has signed today an exclusive license agreement (the "Agreement") with Maruho Co, Ltd, Osaka, Japan ("Maruho") for the development and commercialization of Ameluz® for all indications in East Asia and Oceania, based on the term sheet agreed on March 3, 2020 (see ad hoc release of March 3, 2020). Under the terms of the Agreement, Maruho will obtain exclusive development and commercialization rights including the right to sublicense for Ameluz® in Japan, China, Korea, India, Pakistan, Vietnam, the Philippines, Australia, New Zealand as well as the surrounding countries and islands (the “Territory”).
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that the European Commission has approved the use of Biofrontera’s prescription drug Ameluz® in combination with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) on the extremities and trunk/neck. With a recurrence rate of 19.5%, Ameluz® showed lower recurrence rates after 12 months than Metvix with 31.2%.
Leverkusen, Germany, April 09, 2020 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.
The Executive Board of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today resolved, with the approval of the Supervisory Board, to issue two qualified subordinated mandatory convertible bonds. The following are to be issued (i) 0.5 % qualified subordinated mandatory convertible bond 2020/2024 and (ii) 1.0 % qualified subordinated mandatory convertible bond 2020/2026. Both mandatory convertible bonds consist of up to 1,600,000 bonds with a principal amount of EUR 5.00 each and a total principal amount of up to EUR 8,000,000.
CEBU CITY, Philippines – The Central Bangus Hatchery (CBH) of the Bureau of Fisheries and Aquatic Resources in Central Visayas (BFAR-7) that is located in Pangangan Island, Calape town in Bohol province recorded the highest production of milkfish or “bangus” …
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an update on its clinical developments. On February 3, 2020, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion with respect to our submission for the Ameluz® label extension for the treatment of actinic keratosis (AK) on the extremities and trunk/neck. In addition, the results of the follow-up phase of the clinical comparison study for daylight PDT with Ameluz® and Metvix® will be included in the product information (SmPC).
Leverkusen, Germany, March 23, 2020 -- On February 26, 2020, the Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible.
Leverkusen, Germany, March 12, 2020 -- On February 26, 2020, Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible bonds.
Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, announces that it has entered into a Binding Term Sheet with Maruho Co, Ltd, Osaka, Japan ("Maruho"), which sets out the main terms of a future license agreement. The agreement covers the commercialization of Ameluz® by Maruho in East Asia and Oceania. Biofrontera AG grants Maruho an exclusive license to develop and market Ameluz® for all indications in East Asia and Oceania.
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first three months of fiscal year 2020. The preliminary unaudited revenue of the Company for the period January 1 to March 31, 2020 was in the range of EUR 6.4 to 6.6 million. The current COVID-19 pandemic had a major impact on the Company’s business, with very little sales in particular in the second half of March.
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or “Biofrontera”), an international biopharmaceutical company, today comments on certain litigation in California state court between the Company and DUSA Pharmaceuticals, Inc. (“DUSA”). In 2018, the Company sued DUSA Pharmaceuticals, Inc. in California state court alleging that DUSA engaged in unfair competition by providing excessive product samples to physicians and by using its distributor to inflate product prices. After filing suit, DUSA stopped using Foundation Care as its distributor to dispense its drug products, which was in substantial part the Company’s goal in filing this lawsuit.
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2020 and provided an update on recent developments. This was due to the COVID-19 pandemic, which had a significant negative impact on business development.
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the full year ended December 31, 2019 and provided an update on recent operational and clinical developments. Cash and cash equivalents were EUR 11.1 million as of December 31, 2019 compared to EUR 19.5 million as of December 31, 2018.
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion with respect to Biofrontera’s submission for label extension for its topical prescription drug Ameluz®. The extended approval will include photodynamic therapy (PDT) of mild and moderate actinic keratoses (AK) on the extremities and trunk/neck.
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that it has reorganized its European sales structure. The operational change was preceded by the reorganization of the Company’s US-subsidiary Biofrontera Inc. (published on 5 January 2020). As part of the restructuring of Biofrontera, Christoph Dünwald, Chief Commercial Officer (CCO), has resigned from his position to pursue new challenges.
Now, may I hand you over to Pamela Keck, Head of Investor Relations, who will lead you through this conference. Yesterday, we issued a press release announcing financial results for the three months ended March 31st, 2020.
Leverkusen, Germany, May 12, 2020 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing.